Roche pays €70M upfront for Tusk’s preclinical Treg depleter

Roche pays €70M upfront for Tusk’s preclinical Treg depleter

Source: 
Fierce Biotech
snippet: 

Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests.